These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29913079)

  • 1. Long-term management of Parkinson's disease using levodopa combinations.
    Müller T; Möhr JD
    Expert Opin Pharmacother; 2018 Jun; 19(9):1003-1011. PubMed ID: 29913079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2020 May; 16(5):403-414. PubMed ID: 32238065
    [No Abstract]   [Full Text] [Related]  

  • 3. The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.
    Stocchi F
    Expert Opin Pharmacother; 2006 Jul; 7(10):1399-407. PubMed ID: 16805724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opicapone: A Review in Parkinson's Disease.
    Scott LJ
    Drugs; 2016 Sep; 76(13):1293-1300. PubMed ID: 27498199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
    Chen JJ; Fernandez HH
    Drugs Aging; 2007; 24(8):663-80. PubMed ID: 17702535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa.
    Melamed E; Zoldan J; Galili-Mosberg R; Ziv I; Djaldetti R
    J Neural Transm Suppl; 1999; 56():173-83. PubMed ID: 10370911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
    Müller T
    Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of current and novel levodopa formulations for the treatment of Parkinson's disease.
    Jimenez-Shahed J
    Ther Deliv; 2016; 7(3):179-91. PubMed ID: 26893250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa in Parkinson's Disease: Current Status and Future Developments.
    Tambasco N; Romoli M; Calabresi P
    Curr Neuropharmacol; 2018; 16(8):1239-1252. PubMed ID: 28494719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.
    Gottwald MD
    Pharmacotherapy; 1999 Nov; 19(11 Pt 2):162S-8S. PubMed ID: 10555944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interventions to achieve tonic exposure to levodopa: delaying or preventing the onset of motor complications.
    Luer MS
    Pharmacotherapy; 1999 Nov; 19(11 Pt 2):169S-79S. PubMed ID: 10555945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O
    Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology review of opicapone for the treatment of Parkinson's disease.
    Fabbri M; Rosa MM; Ferreira JJ
    Neurodegener Dis Manag; 2016 Oct; 6(5):349-62. PubMed ID: 27599671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting levodopa effects in Parkinson's disease.
    Ogawa N
    Acta Med Okayama; 2000 Jun; 54(3):95-101. PubMed ID: 10925733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
    Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I
    J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson"s disease patients experiencing motor fluctuations with levodopa.
    Okereke CS
    J Pharm Pharm Sci; 2002; 5(2):146-61. PubMed ID: 12207867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson's disease.
    Müller T
    Expert Rev Neurother; 2013 Jun; 13(6):707-18. PubMed ID: 23739007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa in Parkinson's disease: from the past to the future.
    Pezzoli G; Zini M
    Expert Opin Pharmacother; 2010 Mar; 11(4):627-35. PubMed ID: 20163273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
    Nutt JG; Carter JH; Lea ES; Woodward WR
    Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.